Testing a new antibiotic for drug-resistant pneumonia in the hospital
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 82 years old.
- You have pneumonia that started in the hospital or while on a breathing machine.
- Your pneumonia is caused by a type of bacteria that is resistant to many common antibiotics.
- You have not received more than 48 hours of antibiotics that would work against this bacteria before starting the study drug, or you are getting worse on your current treatment.
- You do not have serious kidney, liver, or heart problems, or certain other severe health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of antibiotics (BV100, polymyxin B, and either ceftazidime/avibactam or cefiderocol) for serious lung or bloodstream infections caused by a tough-to-treat bacteria called Acinetobacter. The goal is to see if the combination is safe and works better than current treatments.
This trial tests a new antibiotic called HRS-8427 for adults with bacterial pneumonia that started in the hospital or while on a ventilator. It may be an option if you need IV antibiotics and haven't already received long-term treatment for this infection.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
This trial tests a new antibiotic called YK-1169 compared to a standard antibiotic (ceftazidime-avibactam) in adults with serious lung infections acquired in hospitals or from ventilators. The goal is to see if YK-1169 works as well or better at treating these infections.
This study compares an experimental antibiotic called ASK0912 with an approved antibiotic (polymyxin B) in adults with hospital-acquired or ventilator-associated pneumonia. It aims to see if the new drug is as effective and safe as the standard treatment.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
Hear when a new Hospital-acquired Bacterial Pneumonia (HABP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.